Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in North Dakota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 334 | 20% |
| 2020 | 7 | 349 | 22% |
| 2021 | 10 | 353 | 25% |
| 2022 | 9 | 353 | 29% |
| 2023 | 11 | 468 | 34% |
| 2024 | 15 | 600 | 37% |
| 2025 from claims | – | 764 618–897 | 39% |
| 2026 forecast | – | 845 662–1,061 | 38% |
| 2027 forecast | – | 920 682–1,217 | 39% |
| 2028 forecast | – | 1,002 710–1,384 | 40% |
| 2029 forecast | – | 1,092 742–1,565 | 41% |
| 2030 forecast | – | 1,188 779–1,764 | 41% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 87% of the cases CMS names in North Dakota; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 60% inpatient hospital, 40% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~840 | ~510 | ~330 |
| 2027 · ~920 | ~560 | ~350 |
| 2028 · ~1,000 | ~620 | ~380 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 38% (40% in 2025), inpatient hospital about 61% (60% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 125 | 4,051+13%/yr | +13%/yr | 2.6 | 15% | 6,990 in 2030+9.5%/yr |
| Ohio | 94 | 3,603+4.6%/yr | +4.6%/yr | 2.8 | 1% | 6,180 in 2030+9.4%/yr |
| Michigan | 82 | 3,065+2.7%/yr | +2.7%/yr | 3.1 | 17% | 4,880 in 2030+8.1%/yr |
| Indiana | 68 | 2,697+18%/yr | +18%/yr | 3.3 | 0% | 4,650 in 2030+9.5%/yr |
| Kansas | 56 | 2,663+15%/yr | +15%/yr | 6.0 | 5% | 4,850 in 2030+10%/yr |
| Missouri | 58 | 2,381+6.1%/yr | +6.1%/yr | 3.3 | 1% | 3,950 in 2030+8.8%/yr |
| Wisconsin | 50 | 1,796+14%/yr | +14%/yr | 2.7 | 0% | 3,250 in 2030+10%/yr |
| Minnesota | 42 | 1,476+9.6%/yr | +9.6%/yr | 2.8 | 3% | 3,650 in 2030+16%/yr |
| Nebraska | 22 | 1,071+16%/yr | +16%/yr | 3.8 | 3% | 1,730 in 2030+8.3%/yr |
| Iowa | 21 | 859+11%/yr | +11%/yr | 1.8 | 5% | 1,760 in 2030+13%/yr |
| South Dakota | 11 | 481+17%/yr | +17%/yr | 3.4 | 0% | 890 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 10 | 559−1.6%/yr | −1.6%/yr | 5.81.1× | 0% | 640 in 2030+2.2%/yr |
| EP ablation | 5 | 223+7.5%/yr | +7.5%/yr | 2.00.6× | 0% | 500 in 2030+15%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in North Dakota · Every state · Compare with Illinois
Boston Scientific leads with 51% of company spending on these surgeons in 2025, −11 pts on 2024.
In 2025, 4 companies reported engagement with North Dakota’s surgeons worth $2,548 in consulting, speaking, meals and travel tied to these products, about $170 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.